×

Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer

  • US 10,280,468 B2
  • Filed: 02/09/2015
  • Issued: 05/07/2019
  • Est. Priority Date: 02/07/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method for diagnosing and treating a patient suffering from a subtype of cancer which is resistant to anti-angiogenic therapy, comprising:

  • obtaining a cancer sample from the patient;

    measuring expression levels of a biomarker panel in the cancer sample, wherein the biomarker panel is a ten-biomarker panel comprising at least IGF2, TAP1, SHISA4, ENTPD7, CDR1, SPARC, INS, NUAK1, and MATN3;

    determining a cancer sample expression score for the biomarker panel based on the measured expression levels;

    comparing the cancer sample expression score to a threshold expression score, derived from a cohort of patients with a known status of responsiveness to an anti-angiogenic agent; and

    treating the patient with at least one of a platinum-based chemotherapeutic agent and a mitotic inhibitor, but not an anti-angiogenic agent if the cancer sample expression score is above or equal to the threshold expression score.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×